Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2025

Description

List of Tables

GlobalData's clinical trial report, "Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2025" provides an overview of Idiopathic Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Product Code: GDHC7266CTIDB

List of Tables

List of Figures

Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Idiopathic Pulmonary Fibrosis
Aug 26, 2025: Calluna Pharma Announces Initiation of Phase 2 Aurora Study of CAL101 for Idiopathic Pulmonary Fibrosis
Aug 21, 2025: Puretech Showcases Differentiated Development Strategy, and Spotlights Phase 2B Data Positioning Deupirfenidone as a Potential Standard of Care in IPF
Aug 19, 2025: Rein Therapeutics Wins U.K. Approval To Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Aug 14, 2025: Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Jul 31, 2025: GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")
Jul 16, 2025: Endeavor BioMedicines Receives ODD from the U.S. FDA and European Commission for Taladegib for the Treatment of Idiopathic Pulmonary Fibrosis
Jul 15, 2025: Cereno Announces Positive Topline Results From Phase I Trial of CS014 - A Novel HDAC Inhibitor - Supporting Advancement Into Phase II
Jul 11, 2025: Rein Therapeutics Announces Update on LTI-03
Jul 01, 2025: Gri Bio Completes Enrollment in Phase 2A Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")
Jun 30, 2025: Cereno Scientific Shares That the Top-Line Results of the CS014 Phase I Trial Will Be Communicated in Mid-July
Jun 26, 2025: GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2A Study in IPF
Jun 25, 2025: Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Jun 16, 2025: The Participation of 26 Spanish Hospitals and 142 Patients in Two Global Clinical Trials Contributes to Bringing New Solutions in Pulmonary Fibrosis
Jun 10, 2025: Rein Therapeutics Pauses Enrollment and Patient Dosing for Phase 2 RENEW Trial of LTI-03
Jun 05, 2025: Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
Jun 03, 2025: Insilico Medicine Announces Publication of Phase IIa Results Evaluating Rentosertib, Novel TNIK Inhibitor for IPF Discovered with Pioneering AI
Jun 03, 2025: Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Jun 02, 2025: Trevi Therapeutics Announces Positive Topline Results From the Phase 2B Coral Trial of Haduvio in Patients With IPF Chronic Cough
Jun 01, 2025: Trevi to Host Conference Call to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with IPF Chronic Cough
Clinical Trial Profile Snapshots

Appendix

Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source

Product Code: GDHC7266CTIDB

List of Table

List of Tables

Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*

List of Figure

List of Figures

Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
GlobalData Methodology

Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2025

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

Appendix

List of Table

List of Tables

List of Figure

List of Figures